Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Crosses Above 200 Day Moving Average - What's Next?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report) shares crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $3.96 and traded as high as $5.68. Cumberland Pharmaceuticals shares last traded at $5.67, with a volume of 9,770 shares trading hands.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised shares of Cumberland Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 8th.

Cumberland Pharmaceuticals Price Performance

The company has a quick ratio of 0.99, a current ratio of 1.13 and a debt-to-equity ratio of 0.41. The stock has a market cap of $78.40 million, a price-to-earnings ratio of -6.81 and a beta of -0.29. The company's 50-day moving average is $4.96 and its 200-day moving average is $4.02.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $0.15 earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a negative net margin of 29.54% and a negative return on equity of 9.50%.

Institutional Trading of Cumberland Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Berkshire Asset Management LLC PA acquired a new stake in shares of Cumberland Pharmaceuticals during the first quarter worth approximately $692,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Cumberland Pharmaceuticals during the first quarter worth approximately $634,000. Informed Momentum Co LLC acquired a new stake in shares of Cumberland Pharmaceuticals during the first quarter worth approximately $304,000. Walleye Capital LLC acquired a new stake in shares of Cumberland Pharmaceuticals during the first quarter worth approximately $298,000. Finally, Two Sigma Investments LP increased its holdings in shares of Cumberland Pharmaceuticals by 94.3% during the fourth quarter. Two Sigma Investments LP now owns 37,649 shares of the specialty pharmaceutical company's stock worth $89,000 after buying an additional 18,271 shares in the last quarter. Institutional investors and hedge funds own 15.51% of the company's stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.